185 related articles for article (PubMed ID: 2028562)
21. Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells.
Hermann GG; Petersen KR; Zeuthen J; Steven K
Scand J Urol Nephrol; 1991; 25(4):269-73. PubMed ID: 1780700
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Fair WR; Whitmore WF; Melamed MR
J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
[TBL] [Abstract][Full Text] [Related]
23. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
de Boer EC; De Reijke TM; Vos PC; Kurth KH; Schamhart DH
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
[TBL] [Abstract][Full Text] [Related]
24. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
[TBL] [Abstract][Full Text] [Related]
25. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
Witjes JA; vd Meijden AP; Doesburg W; Debruyne FM
Eur Urol; 1993; 23(3):366-70. PubMed ID: 8508889
[TBL] [Abstract][Full Text] [Related]
26. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
27. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
29. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
30. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
31. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
32. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
Haaff EO; Catalona WJ; Ratliff TL
J Urol; 1986 Oct; 136(4):970-4. PubMed ID: 3489840
[TBL] [Abstract][Full Text] [Related]
33. [Intravesical instillations of BCG and bladder carcinoma in situ].
Haab F; Dauge MC; Delmas V; Boccon-Gibod L
Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
[TBL] [Abstract][Full Text] [Related]
34. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
35. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
36. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
37. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
38. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
39. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
